DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis

Content tools

Share it

For every 5 radiological vertebral fractures avoided there is one case of thromboembolism

Bazedoxifene is indicated in postmenopausal osteoporosis in women at increased risk of fracture.
It is not effective in the reduction of clinical fractures, hip or non-vertebral fractures, and has only shown a significant reduction in the incidence of morphometric-diagnosed vertebral fractures.
The increase in the incidence of thromboembolism is similar to that observed with raloxifene. The EMA has established a risk management plan to study some alarm signals detected.
Its price is considerably higher than raloxifene.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *